Source comparison
Tesamorelin Dosage Lipodystrophy 2026: Comparison Table
2mg SC daily (standard) 15.2% mean reduction 30% injection site reactions, 12% arthralgia FDA-approved for HIV lipodystrophy First-line therapy. Established efficacy and safety profile 1mg SC daily (reduced) 8–10% reduction (estimated from dose-ranging data) L
This comparison does not assign a generated winner or score.
- 2mg SC daily (standard)
- 15.2% mean reduction
- 30% injection site reactions, 12% arthralgia
- FDA-approved for HIV lipodystrophy
- First-line therapy. Established efficacy and safety profile
- 1mg SC daily (reduced)
- 8–10% reduction (estimated from dose-ranging data)
- Lower injection site reaction rate (~20%)
- Off-label
- Consider only in patients intolerant to 2mg who show partial response
- 3mg SC daily (escalated)
- 16–18% reduction (investigational data)
- 45% injection site reactions, 22% arthralgia, elevated IGF-1
- Off-label, not recommended
- No additional VAT benefit justifies increased adverse event burden
- Intermittent dosing (5 days/week)
- Limited data, estimated 10–12% reduction
- Variable. Adherence pattern complicates interpretation
- Not recommended. Breaks physiological GH pulsatility pattern